Evaluating the Potential Benefits of Using Sustained Response as a Prognostic Factor in Intermediate Hepatocellular Carcinoma Following Treatment With Conventional Chemoembolization

JAMA Netw Open. 2018 Oct 5;1(6):e183209. doi: 10.1001/jamanetworkopen.2018.3209.

Author

Jesse A Berlin¹

Affiliation

¹ Johnson & Johnson, Epidemiology, Titusville, New Jersey.

PMID: 30646216
DOI: 10.1001/jamanetworkopen.2018.3209

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Hepatocellular*
Chemoembolization, Therapeutic*
Humans
Kaplan-Meier Estimate
Liver Neoplasms*
Prognosis